Abstract: It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.

Abstract: It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.

Abstract: The release of bradykinin into the circulatory system is potentiated by administration of a polypeptide having an amino acid sequence corresponding to domain 3 of the human kininogen heavy chain. The polypeptide competitively inhibits the binding of high and low molecular weight kininogen to platelets and other cells which protect the kininogens from kallikrein cleavage, thereby increasing the level of bradykinin in the cirulation. The resulting in vivo effect is an intravascular elevation of bradykinin and concomitant lowering of blood pressure. The domain 3 polypeptide also inhibits thrombin-induced platelet and endothelial cell activation.